naxagolide has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 7 (63.64) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, GM; Brainard, DL; Gordon, SW; Grothusen, JR; Hichens, M; Schwartzman, RJ | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ | 2 |
| de Yébenes, JG; Fahn, S; Goodman, R; Jamrosik, Z; Pezzoli, G; Popalski, S | 1 |
| Bondi, JV; Hand, E; Hichens, M; Iversen, SD; Jennings, CA; Loper, AE; Rupniak, NM; Stahl, SM; Tye, SJ | 1 |
| Jenner, P; Marsden, CD; Nomoto, M; Stahl, S | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA; Stahl, SM | 1 |
| Guillén, J; Laguna, J; Luquin, MR; Martínez-Lage, JM; Obeso, JA | 1 |
| Bankiewicz, KS; Belluzzi, JD; Domino, EF; May, JM; McAfee, DA | 1 |
| Herrero, MT; Laguna, J; Luquin, MR; Obeso, JA | 1 |
| Goulet, M; Madras, BK | 1 |
11 other study(ies) available for naxagolide and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine | 1991 |
(+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Antiparkinson Agents; Athetosis; Chorea; Dopamine Agents; Levodopa; Oxazines; Saimiri | 1990 |
Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Agents; Injections, Intraventricular; Macaca fascicularis; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Rats; Receptors, Dopamine | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri | 1990 |
Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Antiparkinson Agents; Behavior, Animal; Male; Oxazines; Parkinson Disease, Secondary; Pyridines; Saimiri | 1989 |
Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Dopamine Agents; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Pyridines | 1987 |
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Pyridines | 1988 |
The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Dopamine Agents; Excitatory Amino Acid Antagonists; Ibotenic Acid; Indoles; Macaca fascicularis; Motor Activity; Oxazines; Parkinson Disease; Phenanthridines; Quinoxalines; Receptors, AMPA; Receptors, Glutamate | 1993 |
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Dominance, Cerebral; Dopamine Agents; Female; Injections, Intramuscular; Macaca nemestrina; Male; Oxazines; Oxidopamine; Parkinson Disease, Secondary; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes | 1994 |
Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agents; Drug Tolerance; Female; Macaca fascicularis; Male; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Psychomotor Performance | 1993 |
D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Macaca fascicularis; Male; Motor Activity; Motor Skills; Oxazines; Parkinsonian Disorders; Phenanthridines; Quinolines; Receptors, Dopamine D1 | 2000 |